Download Now

Your Token Count

0

Sign in to Purchase/Download Documents

Sign in / Register

User login

Social Networking

Support Free Media

Fenofibrates

User Options

A Membership is required. Please Login or Create an account to get started

Request us to build a Downloadable Document Product on this Topic

Make a Request for GMI to add more Articles on this Topic Immediately (Purchase Required)

View a Printer Friendly version of this page

E-mail this page to a friend

Perform a Search with this Topic

Hover over an icon for more information

Additional Topics Details for this Page

Article Count - 19
Cumulative Knowledge - 133

Advanced Database Options

Limit Articles Displayed by the Following Study Types

Available Sorting Options

Limited to Members Only

By default, all articles on GreenMedInfo.com are sorted based on the content type which best reflects the data which most users are searching for. For instance, people viewing substances are generally most interested in viewing diseases that these substances have shown to have positive influences. This section is for allowing more advanced sorting methods. Currently, these advanced sorting methods are available for members only. If you are already a member, you can sign in by clicking here. If you do not currently have a user account, and would like to create one/become a member, click here to begin the singup process.

Currently Available Sorting Options

Article Published Date - Sort all displayed articles by their published date
Quick Summary Fieldsets - Sort alphabetically, rather than by Cumulative Knowledge
Cumulative Knowledge - Default sorting method. Allows you to sort descendingly

What is Cumulative Knowledge?

Cumulative Knowledge is determined by ascribing a numerical value to the various study types weighted in descending order as follows: (1) Meta-Analysis; (2) Human Study; (3) Human: Case Study; (4) Animal: Transgenic; (5) Animal; (6) In Vitro; (7) Review; and (8) Commentary.

Click here for a more thorough explanation.

Quick Summary: Current access displays 2 out of 25 associated Diseases

Name	Cumulative Knowledge	Article Count	Focus Articles
Statin-Induced Pathologies	58	8	Log in \| Sign up
Erectile Dysfunction	31	3	Log in \| Sign up

Quick Summary: Current access displays 2 out of 7 associated Adverse Pharmacological Actions

Name	Cumulative Knowledge	Article Count	Focus Articles
Nephrotoxic	25	4	Log in \| Sign up
Neurotoxic	20	2	Log in \| Sign up

Currently Viewing Free Sample of Member Only Features

Although all 19,000+ articles on GreenMedInfo.com are made entirely free to view as an educational service to the public, we provide a powerful set of enhanced data comprehension and retrieval tools for subscribing members. Above you are viewing a free preview, limited to 2 rows, of the membership feature called "Cumulative Knowledge" (learn more).

The Focus Article Feature is not enabled.

Upgrading to the Member role gives you access to unlimited rows of Cumulative Knowledge data.

To Participate

Click here to login
Click here to create an account

View the Evidence: Problem Substances

A combination of ezetimibe and simvastatin do not reduce aortic valve stenosis.

Click here to read the entire abstract

Pubmed Data : Am J Cardiol. 2010 Dec 1;106(11):1634-9. Epub 2010 Oct 14. PMID: 21094366

Article Published Date : Dec 01, 2010

Study Type : Meta Analysis

Additional Links

Diseases : Aortic Stenosis : CK(44) : AC(11)

Problem Substances : Ezetimibe (trade name Zetia) : CK(30) : AC(2), Simvastatin : CK(713) : AC(143)

Lipid-lowering drugs contribute to erectile dysfunction.

Click here to read the entire abstract

Pubmed Data : Fam Pract. 2002 Feb ;19(1):95-8. PMID: 11818357

Article Published Date : Feb 01, 2002

Study Type : Meta Analysis

Additional Links

Diseases : Erectile Dysfunction : CK(510) : AC(41), Statin-Induced Pathologies : CK(1570) : AC(315)

Problem Substances : Cholesterol Lowering Drugs : CK(2146) : AC(349), Fenofibrates : CK(133) : AC(19), Statin Drugs : CK(3969) : AC(465)

Decreases in high-density lipoprotein cholesterol with fenofibrate are a quite common phenomenon.

Click here to read the entire abstract

Pubmed Data : J Clin Pathol. 2009 Mar;62(3):250-3. PMID: 19251953

Article Published Date : Mar 01, 2009

Study Type : Human Study

Additional Links

Diseases : Cholesterol: LDL/HDL ratio : CK(432) : AC(58), Dyslipidemias : CK(176) : AC(33), HDL: Low : CK(255) : AC(45)

Problem Substances : Fenofibrates : CK(133) : AC(19)

Adverse Pharmacological Actions : Dyslipidemic : CK(22) : AC(7)

Fenofibrates therapy is associated with deterioration of renal function.

Click here to read the entire abstract

Pubmed Data : Clin Nephrol. 2001 Jan;55(1):39-44. PMID: 11200866

Article Published Date : Jan 01, 2001

Study Type : Human Study

Additional Links

Diseases : Hyperlipidemia : CK(1211) : AC(109), Kidney Damage: Drug-Induced : CK(86) : AC(22)

Problem Substances : Fenofibrates : CK(133) : AC(19)

Adverse Pharmacological Actions : Nephrotoxic : CK(162) : AC(38)

Fibrate-induced deterioration of renal function has been reported.

Click here to read the entire abstract

Pubmed Data : Nefrologia. 2009;29(3):208-13. PMID: 19554053

Article Published Date : Jan 01, 2009

Study Type : Human Study

Additional Links

Diseases : Kidney Damage: Drug-Induced : CK(86) : AC(22)

Problem Substances : Fenofibrates : CK(133) : AC(19)

Adverse Pharmacological Actions : Nephrotoxic : CK(162) : AC(38)

Lipid lowering drugs increase the risk of peripheral neuropathy.

Click here to read the entire abstract

Pubmed Data : J Epidemiol Community Health. 2004 Dec ;58(12):1047-51. PMID: 15547071

Article Published Date : Dec 01, 2004

Study Type : Human Study

Additional Links

Diseases : Peripheral Neuropathies : CK(394) : AC(31), Statin-Induced Pathologies : CK(1570) : AC(315)

Problem Substances : Cholesterol Lowering Drugs : CK(2146) : AC(349), Fenofibrates : CK(133) : AC(19), Statin Drugs : CK(3969) : AC(465)

Adverse Pharmacological Actions : Neurotoxic : CK(1076) : AC(179)

Men treated with cholesterol-lowering drugs complain more frequently of erectile dysfunction.

Click here to read the entire abstract

Pubmed Data : J Clin Pharm Ther. 1996 Apr ;21(2):89-94. PMID: 8809645

Article Published Date : Apr 01, 1996

Study Type : Human Study

Additional Links

Diseases : Erectile Dysfunction : CK(510) : AC(41), Statin-Induced Pathologies : CK(1570) : AC(315)

Problem Substances : Cholesterol Lowering Drugs : CK(2146) : AC(349), Fenofibrates : CK(133) : AC(19), Statin Drugs : CK(3969) : AC(465)

Adverse Pharmacological Actions : Endocrine Disruptor : CK(478) : AC(81)

Psychiatric adverse reactions associated with cholesterol-lowering drugs have been reported.

Click here to read the entire abstract

Pubmed Data : Drug Saf. 2007 ;30(3):195-201. PMID: 17343428

Article Published Date : Jan 01, 2007

Study Type : Human Study

Additional Links

Diseases : Aggression : CK(143) : AC(15), Depression : CK(674) : AC(88), Memory Disorders: Drug-Induced : CK(77) : AC(12), Psychiatric Disorders : CK(71) : AC(10), Statin-Induced Pathologies : CK(1570) : AC(315)

Pharmacological Actions : Anticholesteremic Agents : CK(669) : AC(142)

Problem Substances : Fenofibrates : CK(133) : AC(19), Statin Drugs : CK(3969) : AC(465)

Adverse Pharmacological Actions : Neurotoxic : CK(1076) : AC(179)

Statin drugs contribute to insulin resistance in human subjects.

Click here to read the entire abstract

Pubmed Data : Int J Clin Pract. 2011 Nov ;65(11):1141-8. PMID: 21995692

Article Published Date : Nov 01, 2011

Study Type : Human Study

Additional Links

Diseases : Insulin Resistance : CK(1034) : AC(221)

Problem Substances : Ezetimibe (trade name Zetia) : CK(30) : AC(2), Rosuvastatin : CK(68) : AC(16), Simvastatin : CK(713) : AC(143), Statin Drugs : CK(3969) : AC(465)

Adverse Pharmacological Actions : Endocrine Disruptor: Insulin Resistance : CK(152) : AC(31)

A possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil has been reported.

Click here to read the entire abstract

Pubmed Data : J Intern Med. 1996 Dec ;240(6):403-4. PMID: 9010388

Article Published Date : Dec 01, 1996

Study Type : Human: Case Report

Additional Links

Diseases : Rhabdomyolysis : CK(165) : AC(38), Statin-Induced Pathologies : CK(1570) : AC(315)

Additional Keywords : Drug Synergy : CK(327) : AC(147)

Problem Substances : Fenofibrates : CK(133) : AC(19), Gemfibrozil : CK(3) : AC(1), Simvastatin : CK(713) : AC(143)

Adverse Pharmacological Actions : Myotoxicity : CK(317) : AC(79)

Acute cholestatic hepatitis induced by fenofibrate has been reported.

Click here to read the entire abstract

Pubmed Data : J Clin Pharm Ther. 2009 Oct;34(5):599-602. PMID: 19744016

Article Published Date : Oct 01, 2009

Study Type : Human: Case Report

Additional Links

Diseases : Chemically-Induced Liver Damage : CK(475) : AC(175), Drug-Induced Toxicity : CK(560) : AC(78), Hepatitis : CK(64) : AC(23)

Problem Substances : Fenofibrates : CK(133) : AC(19)

Adverse Pharmacological Actions : Hepatotoxic : CK(283) : AC(80)

Acute renal failure with the combined use of rosuvastatin and fenofibrate has been reported.

Click here to read the entire abstract

Pubmed Data : Ren Fail. 2010 Jun;32(5):633-5. PMID: 20486848

Article Published Date : Jun 01, 2010

Study Type : Human: Case Report

Additional Links

Diseases : Kidney Failure: Acute : CK(51) : AC(11)

Problem Substances : Fenofibrates : CK(133) : AC(19), Rosuvastatin : CK(68) : AC(16), Statin Drugs : CK(3969) : AC(465)

Adverse Pharmacological Actions : Nephrotoxic : CK(162) : AC(38)

Pancreatitis associated with simvastatin plus fenofibrate.

Click here to read the entire abstract

Pubmed Data : Ann Pharmacother. 2002 Feb ;36(2):275-9. PMID: 11847949

Article Published Date : Feb 01, 2002

Study Type : Human: Case Report

Additional Links

Diseases : Pancreatitis : CK(164) : AC(40), Statin-Induced Pathologies : CK(1570) : AC(315)

Problem Substances : Fenofibrates : CK(133) : AC(19), Simvastatin : CK(713) : AC(143)

Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction has been reported.

Click here to read the entire abstract

Pubmed Data : Endocr Pract. 2010 May-Jun;16(3):382-8. PMID: 20061291

Article Published Date : May 01, 2010

Study Type : Human: Case Report

Additional Links

Diseases : Cholesterol: LDL/HDL ratio : CK(432) : AC(58), Diabetes Mellitus: Type 2 : CK(3429) : AC(341), HDL: Low : CK(255) : AC(45)

Problem Substances : Fenofibrates : CK(133) : AC(19), Rosiglitazone (trade name Avandia) : CK(106) : AC(15)

Clofibrate induces skeletal muscle lesions in rats.

Click here to read the entire abstract

Pubmed Data : Toxicol Pathol. 2007;35(4):517-20. PMID: 17562484

Article Published Date : Jan 01, 2007

Study Type : Animal Study

Additional Links

Diseases : Drug-Induced Toxicity : CK(560) : AC(78)

Problem Substances : Fenofibrates : CK(133) : AC(19)

Fenofibrate induce muscular toxicity in rats.

Click here to read the entire abstract

Pubmed Data : Toxicol Pathol. 2009;37(4):517-20. Epub 2009 Apr 24. PMID: 19395589

Article Published Date : Jan 01, 2009

Study Type : Animal Study

Additional Links

Diseases : Myopathies : CK(252) : AC(51)

Problem Substances : Fenofibrates : CK(133) : AC(19)

Adverse Pharmacological Actions : Nephrotoxic : CK(162) : AC(38)

Fenofibrate-induced myopathy may be due to its adverse effect in the liver.

Click here to read the entire abstract

Pubmed Data : Toxicology. 2009 Dec 21;266(1-3):1-5. Epub 2009 Oct 9. PMID: 19819289

Article Published Date : Dec 21, 2009

Study Type : Animal Study

Additional Links

Diseases : Drug-Induced Toxicity : CK(560) : AC(78), Myopathies : CK(252) : AC(51)

Problem Substances : Fenofibrates : CK(133) : AC(19)

Adverse Pharmacological Actions : Hepatotoxic : CK(283) : AC(80)

Lipid-lowering drugs may contribute to erectile dysfunction.

Click here to read the entire abstract

Article Publish Status : This is a free article. Click here to read the complete article.

Pubmed Data : Fam Pract. 2002 Oct ;19(5):567. PMID: 12356716

Article Published Date : Oct 01, 2002

Study Type : Review

Additional Links

Diseases : Erectile Dysfunction : CK(510) : AC(41), Statin-Induced Pathologies : CK(1570) : AC(315)

Problem Substances : Cholesterol Lowering Drugs : CK(2146) : AC(349), Fenofibrates : CK(133) : AC(19), Statin Drugs : CK(3969) : AC(465)

Statins and fenofibrates may exert their wide range of adverse side effects through interfering with selenoprotein expression.

Click here to read the entire abstract

Pubmed Data : Trends Cardiovasc Med. 2004 Oct;14(7):273-81. PMID: 15542379

Article Published Date : Oct 01, 2004

Study Type : Review

Additional Links

Diseases : Drug-Induced Nutrient Depletion: Statin Drugs : CK(104) : AC(29), High Cholesterol : CK(1718) : AC(198), Mineral Deficiencies: Selenium : CK(15) : AC(6), Statin-Induced Pathologies : CK(1570) : AC(315)

Additional Keywords : Drug-Nutrient Depletion : CK(64) : AC(7), Statin-Selenium Deficiency : CK(4) : AC(3)

Problem Substances : Fenofibrates : CK(133) : AC(19), Statin Drugs : CK(3969) : AC(465)

Health Guide: Heart Health

Related Blogs

Sugarcane Extract Superior To Cholesterol-Lowering Drugs?

Written by Sayer Ji, Founder

There is a little known natural extract of plant waxes known as policosanol, extractable from sugar cane, yams, and beeswax, which has been giving some of the more profitable drugs on the market a biomedical beating since it was first investigated in clinical trials by the Cubans in the 1990's.

Print Options

Some features are currently member only features. If you are already a member, please login. Otherwise, click here to become a member.

Printer-friendly version
Send to friend
PDF version